newest glp 1 agonist A Closer Look at the Dermatological Profile of GLP-1 Agonists Researchers find GLP-1 medications safe

Interestingly, while Ex4 did not alter saccharin intake during heroin access, a history of Ex4 treatment enhanced saccharin acceptance during extinction trials, suggesting mitigation of heroin-induced devaluation of natural reward

This will grow the market fast

Tirzepatide (Zepbound) A New Treatment for Obstructive Sleep Apnea and Obesity In December 2024, the FDA approved Tirzepatide (Zepbound) for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity

in 2026 from a record high of 39.9% in 2022, according to Gallup

Cyclic AMP, however, is the main intracellular mediator of GLP-1 action in beta cells and other target cell types (27, 65)

Given these exemptions, prescribers must recognize the critical role compounded alternatives continue to play in bridging the affordability and accessibility gap